肺炎链球菌作为斯洛伐克儿童急性中耳炎病因在肺炎球菌结合疫苗时代(2008-2019年)
该观察性研究利用斯洛伐克急性中耳炎(AOM)患儿常规接受鼓膜穿刺术的条件,分析了2008-2019年12年间1,131株肺炎链球菌分离株的血清型和耐药性。结果显示PCV7血清型在2009年引入PCV7后迅速减少并于2014年基本消失,而血清型3和19A(MDR)在PCV10高使用期(2012-2017年)及至2019年始终占最大比例(约2/3)。布拉迪斯拉发地区数据表明PCV接种(77%接种率,主要为PCV13)对<6岁儿童AOM有巨大影响。
要点
- PCV7血清型在2009年引入PCV7后迅速减少,2014年基本消失。
- 血清型3和19A(MDR)在2012-2017年PCV10高使用期及至2019年占肺炎球菌性AOM约2/3。
- 布拉迪斯拉发地区PCV接种率77%(主要为PCV13)对<6岁儿童AOM有巨大影响。
核心结论
- PCV在减少疫苗血清型方面效益巨大;在序贯/并行使用PCVs的情况下,血清型3和(MDR)19A目前占斯洛伐克肺炎球菌性AOM最大比例(约2/3)。
- 该数据将有助于进一步指导儿科医生和家长对肺炎球菌结合疫苗的选择。
研究设计与样本
- 观察性研究,利用斯洛伐克AOM患儿常规接受鼓膜穿刺术的标准诊疗条件,参与儿科耳鼻喉专家将鼓膜穿刺样本送至当地MEDIRIX实验室进行细菌鉴定。
- 12年观察期间(2008-2019年)共检测1,131株分离株,肺炎球菌分离株进行血清分型和抗菌药物耐药性检测;发病率数据仅来自1个地区。
主要发现
- 基于12年1,131株分离株的检测,PCV7血清型在2009年引入PCV7后迅速减少,2014年基本消失。
- PCV10独有血清型(1、5、7F)最大比例为2.7%(2009年),而PCV13额外覆盖的3种血清型(3、6A、19A)自2010年起占肺炎球菌性AOM最大比例,该发现在PCV10市场份额最高时期(2012-2017年)及至观察期末(2019年)保持不变。
- 2012-2017年间不可分型肺炎球菌(<6%)和非PCV13血清型(16-34%)比例增加,但此后再次下降。
- 血清型19A演变为最重要的(多重)耐药肺炎球菌血清型,尤其在PCV10高销售时期(2012-2017年)。
- 布拉迪斯拉发地区发病率数据记录PCV使用(77%接种率,主要为PCV13)对<6岁儿童AOM的巨大影响;血清型19A和3仍是斯洛伐克AOM幼儿中唯一相关的肺炎球菌血清型。
临床怎么用
- 作者认为该数据将有助于进一步指导儿科医生和家长对肺炎球菌结合疫苗的选择。
局限性
- 研究参与度和分型完整性随时间增加。
- 发病率数据仅可从1个地区计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Little data is available on pneumococcal serotypes and their antimicrobial resistance in the pneumococcal conjugate vaccination era in young children with acute otitis media (AOM). Here such data is provided from Slovakia, acountry with sequential introduction and parallel-use of the three commercially available pneumococcal conjugate vaccines (PCVs; PCV7; PCV13; PCV10). METHODS: This observational study takes advantage of the fact that tympanocentesis is the standard of care in children with AOM in Slovakia. Over the 12 year observation period, participating pediatric ENT specialists sent samples taken during tympanocentesis from children with AOM to their local MEDIRIX laboratories for identification of bacteria. Pneumcoccal isolates were serotyped and tested for antimicrobial resistance. Incidence data could be calculated from 1 region. RESULTS: Study participation and completeness of typing increased over time. Based on testing of 1,131 isolates over 12 years, PCV7-serotypes rapidly waned after PCV7 introduction in 2009 and had virtually disappeared in 2014. The maximum fraction of PCV10-only isolates (1, 5, 7F) was 2.7 % (2009) whereas the additional 3 PCV-serotypes (3, 6A, 19A) in PCV13 represented the largest proportion of pneumococcal AOM cases as of 2010. This finding remained unchanged during the period of highest PCV10-market share (2012-2017) and even until the end of the observation period (2019). The fraction of untypeable pneumococci (<6 %) and non-PCV13-serotypes (16-34 %) increased 2012-2017, but decreased again thereafter. Serotype 19A evolved as the most relevant (multidrug-) resistant pneumococcal serotype, again particularly during the time with high sales of PCV10 (2012-2017). Incidence data from the Bratislava region document a huge impact of PCV use (77 % vaccine uptake: mainly PCV13) on AOM in children < 6 years. Serotypes 19A and 3 remain the only relevant pneumococcal serotypes in young Slovakian children with AOM. CONCLUSIONS: As AOM is one of the most common bacterial infections in children < 6 years, the observed benefits of PCVs in reducing vaccine serotypes have been tremendous. With sequential / parallel-use of PCVs, serotypes 3 and (MDR-) 19A today make the largest proportion (about 2/3) of pneumococcal AOM in Slovakia. This data will help to further guide the choice of pneumococcal conjugate vaccines for pediatricians and parents.
引用
- Macaj M, Perdochova L, Jakubikova J, et al. Streptococcus pneumoniae as cause of acute otitis media (AOM) in Slovak children in the pneumococcal conjugate vaccine era (2008-2019). Vaccine. 2022. PMID: 36470684. doi:10.1016/j.vaccine.2022.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。